• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Ziltivekimab associated with multiple proatherogenic inflammatory pathways – secondary analysis of the RESCUE trial

byZoya GomesandYuchen Dai
December 12, 2022
in Cardiology, Chronic Disease, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this secondary analysis of the RESCUE trial, targeted interleukin 6 (IL-6) ligand inhibition with ziltivekimab was associated with a lower neutrophil-lymphocyte ratio (NLR) at week 12, suggesting it may disrupt atherogenic inflammatory pathways, particularly those mediated by myeloid cell compartment.

2. The estimated treatment difference compared with placebo was -14.6%, -15.3% and -23.6% in the 7.5mg, 15-mg, and 30-mg ziltivekimab treatment groups, respectively.  

Evidence Rating Level: 2 (Good) 

Study Rundown: The neutrophil-lymphocyte ratio (NLR) has emerged as an inexpensive biomarker that may assess residual inflammatory risk contributing to atherosclerotic disease progression. Ziltivekimab is a novel therapeutic monoclonal antibody that targets the IL-6 ligand. The Trial to Evaluate Reduction in Inflammation in Patients with Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition (RESCUE) evaluated the effect of ziltivekimab on inflammatory biomarkers in patients at high risk for atherosclerotic disease, including those with chronic kidney disease and elevated high sensitivity C-reactive protein (hsCRP). This secondary analysis aimed to evaluate whether ziltivekimab was associated with a lower NLR compared with a placebo. A total of 264 participants were randomly assigned equally to receive either a placebo, or ziltivekimab 7.5-mg, 15-mg, or 30-mg. The median change in the NLR at 12 weeks was 1.56% in the placebo group, -13.5% in the 7.5-mg group, -14.3% in the 15-mg group, and -22.4% in the 30-mg group. This suggests that ziltivekimab may be associated with multiple proatherogenic inflammatory pathways. Limitations of this study include its modest sample size and brief follow-up period, which did not allow for the assessment of clinical outcomes. 

Click to read the study in JAMA Cardiology

Relevant Reading: The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from 5 contemporary randomized trials

In-Depth [randomized controlled trial]: This study evaluated whether ziltivekimab was associated with a lower NLR compared with placebo through an exploratory post hoc analysis of the RESCUE trial. This was a double-blind, randomized, placebo-controlled, phase 2 trial conducted between June 2019 to January 2020 with 24 weeks of follow-up. Participants were randomly assigned to receive either a placebo or ziltivekimab 7.5-mg, 15-mg or 30-mg subcutaneously every four weeks. The primary outcome was the change in HLR at 12 weeks. A total of 264 participants (median [IQR] age, 68 [60-75] years; 135 men [51%]; 129 women [49%]) were enrolled. The median (IQR) change in the NLR at 12 weeks was 1.56% (IQR, -15.7% to 20.0%), -13.5% (IQR, -31.6% to 3.20%), -14.3% (IQR, -26.9% to 4.62%), and -22.4% (IQR, -33.3% to -4.27%) in the placebo, 7.5 mg, 15 mg, and 30 mg groups respectively. The estimated treatment difference compared with placebo was -14.6% (95% CI, -24.8% to -4.81%; P = .004), -15.3% (95% CI, -25.2% to -5.10%; P = .004), and -23.6% (95% CI, -33.2% to -14.2%; P < .001) in the 7.5-mg, 15-mg, and 30-mg groups, respectively. A similar reduction in the ANC was observed in the same groups. 

RELATED REPORTS

Atherosclerotic risk factors associated with stroke in adulthood present from childhood and increase with age

Absence of coronary plaque among symptomatic patients with high low-density lipoprotein cholesterol levels associated with low risk of atherosclerotic cardiovascular disease events

Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atherosclerorsisinflammatory pathwaysneutrophil-lymphocyte ratioRESCUEZiltivekimab
Previous Post

Study site selection in trials pertaining to transcatheter valvular therapies can affect the socioeconomic makeup of the sample

Next Post

Telemedicine may be associated with improved mental health outcomes

RelatedReports

Patient Basics: Atherosclerosis
Chronic Disease

Atherosclerotic risk factors associated with stroke in adulthood present from childhood and increase with age

August 5, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Absence of coronary plaque among symptomatic patients with high low-density lipoprotein cholesterol levels associated with low risk of atherosclerotic cardiovascular disease events

February 14, 2022
Febuxostat not effective at delaying progression of carotid atherosclerosis in asymptomatic hyperuricemia
Cardiology

Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors

June 10, 2021
Febuxostat not effective at delaying progression of carotid atherosclerosis in asymptomatic hyperuricemia
Cardiology

Evinacumab may be effective in reducing lipid levels in patients with refractory hypercholesterolemia

November 23, 2020
Next Post
Natural language processing may automate data extraction from radiologic reports

Telemedicine may be associated with improved mental health outcomes

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis
  • Active surveillance strategies to improve rates of inferior vena cava filter retrieval
  • Intranasal vaccine against Bordetella pertussis invokes seronegative IgA response
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options